エストラムスチン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H302：飲み込むと有害

  H315：皮膚刺激

  H319：強い眼刺激

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

エストラムスチン 価格

MSDS Information

• Estramustine

エストラムスチン 化学特性,用途語,生産方法

• 用途

  エストロゲン薬前立腺組織に集まり腫瘍の増殖を防ぐと同時に抗アンドロゲン作用も有し抗がん作用を示す

• 効能

  抗悪性腫瘍薬, アルキル化剤

• 使用

  Antineoplastic.

• 定義

  ChEBI: A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.

• 適応症

  Estramustine phosphate sodium (Emcyt) is a hybrid structure combining estradiol and a nitrogen mustard in a single molecule. The drug has been approved for use in prostatic carcinomas and will produce clinical remissions in one-third of patients who have failed to respond to previous estrogen therapy. The mechanism of action of estramustine is not well defined, but it does not appear to require either alkylation of DNA or the presence of estrogen receptors in tumor cells. Nonetheless, the toxicities of the drug are similar to those of estrogen therapy: breast tenderness and enlargement (gynecomastia), fluid retention, mild nausea, and an increased risk of thrombophlebitis and pulmonary embolism.The drug is not myelosuppressive.

• 生物学の機能

  Estramustine has a low affinity for the βm tubulin isotype, which often is overexpressed in estramustineresistant prostatic neoplasms as one defense against this therapeutic intervention.

• 作用機序

  Because this anticancer agent contains a carbamylated nitrogen mustard moiety, it is most commonly classified as a DNA alkylator; however, it is now known that its primary mechanism of antineoplastic action is inhibition of mitosis.

エストラムスチン 上流と下流の製品情報

エストラムスチン 生産企業

Global(90)Suppliers

2998-57-4, エストラムスチン キーワード